Arcutis Biotherapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
ARQT$27.39+4.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity
| ARCUTIS BIOTHERAPEUTICS, INC.Condensed Consolidated Statements of Changes in Stockholders’ Equity(In thousands)(unaudited) | ||||||
|---|---|---|---|---|---|---|
| Common Stock · AdditionalPaid-InCapital · Accumulated Other Comprehensive Loss · AccumulatedDeficit · Total Stockholders’ Equity | ||||||
| Shares · Amount | ||||||
| Balance—December 31, 2025 | 123,333 | $12 | $1,327,595 | $(44) | $(1,138,084) | $189,479 |
| Issuance of common stock upon the exercise of stock options | 135 | — | 1,067 | — | — | 1,067 |
| Issuance of common stock upon the vesting of restricted stock units | 1,574 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 10,867 | — | — | 10,867 |
| Unrealized loss on marketable securities | — | — | — | (351) | — | (351) |
| Foreign currency translation adjustment | — | — | — | (119) | — | (119) |
| Net loss | — | — | — | — | (11,295) | (11,295) |
| Balance—March 31, 2026 | 125,042 | $12 | $1,339,529 | $(514) | $(1,149,379) | $189,648 |
| Common Stock · AdditionalPaid-InCapital · Accumulated Other Comprehensive Loss · AccumulatedDeficit · Total Stockholders’ Equity | ||||||
| Shares · Amount | ||||||
| Balance—December 31, 2024 | 117,848 | $12 | $1,279,479 | $(7) | $(1,121,943) | $157,541 |
| Issuance of common stock upon the exercise of stock options | 110 | — | 395 | — | — | 395 |
| Issuance of common stock upon the vesting of restricted stock units | 1,180 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 9,915 | — | — | 9,915 |
| Unrealized loss on marketable securities | — | — | — | (137) | — | (137) |
| Foreign currency translation adjustment | — | — | — | 4 | — | 4 |
| Net loss | — | — | — | — | (25,060) | (25,060) |
| Balance—March 31, 2025 | 119,138 | $12 | $1,289,789 | $(140) | $(1,147,003) | $142,658 |
See accompanying notes to the condensed consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.